View Older Stories View More Recent Stories
-
BMO Capital: 'Eli Lilly (LLY) Shares Expected to Trade Higher Post ATTAIN-1 Data'
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Lilly's Verzenio shows survival benefit in breast cancer trial
-
HSBC Upgrades Eli Lilly (LLY) to Hold
-
TD Cowen on Eli Lilly (LLY): 'Orfo Successful In ATTAIN-2, Regulatory Submission Underway; Model Updated'
-
William Blair on Orforglipron: 'It is therefore our opinion that orforglipron could be seamlessly incorporated into patients’ daily routines'
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY), 'early innings in obesity still'
-
Immuneering secures clinical supply deal with Lilly for cancer drug combo
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-
JPMorgan on Viking Therapeutic (VKTX): 'we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile'
-
Mizuho: Viking (VKTX) Oral Obesity Program is 'Quite Discouraging'
-
Lilly signs up to $1.3 billion deal with Superluminal for obesity drugs
-
Eli Lilly (LLY) PT Lowered to $825 at Cantor Fitzgerald
-
Eli Lilly (LLY) PT Lowered to $875 at Guggenheim
-
Eli Lilly & Co. (LLY) CEO buys $1 million in stock
-
What to do with Novo Nordisk shares after recent volatility? Barclays explains
-
Eli Lilly & Co. (LLY) sued by Texas for allegedly bribing providers to prescribe company's medications
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Bernstein Sees 'Clear Buying Opportunity' for Eli Lilly (LLY)
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Lowered to $895 at UBS
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
-
Eli Lilly & Co. (LLY) options active on 358K contracts as share price pullback
-
Eli Lilly (LLY) PT Lowered to $905 at Jefferies
-
Leerink Partners Downgrades Eli Lilly (LLY) to Market Perform, 'we no longer expect upward pressure on long-term consensus expectations'
-
Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
-
BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
-
Eli Lilly & Co. (LLY) Tops Q2 EPS by 72c; lifts guidance
-
Stocks expected to have increasing option volume: LLY BDX DDOG WBD QSR PODD RL ZBH H CELH ELAN CROX YETI WRBY PTON
-
Eli Lilly Q2 earnings preview: analysts eye obesity drug sales momentum
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 2.2 calls to 1 put into quarter results
-
Bernstein on Eli Lilly (LLY): 'We've Been Waiting for This'
-
Novo Nordisk (NVO) stock: Where next after profit warning?
-
Trump admin to pilot coverage of weight‑loss drugs under Medicare and Medicaid - WaPo
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
White House: calls on Eli Lilly to take actions within 60 days
-
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
-
Lilly's Mounjaro shows cardiovascular protection in head-to-head trial
-
Deutsche Bank defends Eli Lilly (LLY) on Novo-related sell-off
-
Eli Lilly (LLY) PT Raised to $920 at BMO Capital
-
Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
-
Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
-
Lilly completes Verve Therapeutics acquisition for cardiovascular treatments
-
Eli Lilly receives positive opinion for donanemab in Europe
-
Lilly tender offer for Verve expires with 55.7% of shares tendered
-
BMO Capital on Eli Lilly (LLY): 'ALZ 3 Interim Could Read Positively in Near Future'
